From: Hypersensitivity to oxaliplatin: clinical features and risk factors
Patient characteristics (n = 191) | Mean (range) | n (%) |
---|---|---|
Age (years) | 62.4 (23–84) | |
Sex, male | 78 (41) | |
Atopic diseases | 32 (17) | |
Diagnosis | ||
Colon | 86 (45) | |
Stomach | 10 (5) | |
Ovary | 35 (18) | |
Pancreas | 9 (5) | |
Peritoneum | 8 (4) | |
Rectum | 25 (13) | |
Other1 | 18 (10) | |
Prior platinum exposure, yes | 45 (24) | |
Treament regimen | ||
FOLFOX4 (oxaliplatin, 5-fluorouracil and leucovorin) | 101 (53) | |
FOLFOX4-bevacizumab | 10 (5) | |
FOLFOX4-cetuximab | 4 (2) | |
GEMOX (oxaliplatin and gemcitabine) | 47 (25) | |
Oxaliplatin alone | 5 (3) | |
TOMOX(oxaliplatin and raltitrexed) | 12 (6) | |
Other2 | 12 (6) | |
Total infusion courses | 6.4 (1–18) | |
Oxaliplatin dose (mg/m2) | 85.3 (42–160) |